DUBLIN – Symphogen A/S's main shareholders are putting together a rescue package for the privately held antibody developer comprising DKK390 million (US$58.5 million) in new equity funding, combined with a DKK182 million debt-to-equity conversion. The move would involve a complete write-off of the company's existing share capital, which would cover accrued losses. All warrants would also be canceled.